ArticleMaterials (Basel, Switzerland)2023
Special Issue: "Functionalized Nanomaterials and Structures for Biomedical Applications".
Article in Materials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoscale drug formulations are under wider and wider investigation due to their multiple unique advantages, such as stealth properties which avoid opsonization in the blood stream; specific ligand guided drug delivery to injured cells and tissues; on-demand release in sharp response to a series of endogenous and exogenous stimuli, allowing for predetermined programmed delivery to specific loci in the body and possible timing with circadian rhythms; increased cellular uptake due to their small dimensions and the possibility of intracellular delivery of the therapeutic cargo, especially when functionalized with cell penetrating agents; increased stability in biological fluids; augmented bioavailability; and tailored pharmacokinetics and pharmacodynamics [...].
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.